Clinical Trials in Recurrent Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 771-775 ◽  
Author(s):  
Michael Friedlander ◽  
Edward Trimble ◽  
Anna Tinker ◽  
David Alberts ◽  
Elisabeth Avall-Lundqvist ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Cancer ◽  
Recurrent Ovarian Cancer ◽  
Consensus Conference ◽  
Ca 125 ◽  
Therapeutic Approaches ◽  
Cooperative Research ◽  
International Consensus

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

First-Line Therapy in Ovarian Cancer Trials

2011 ◽  
Vol 21 (4) ◽  
pp. 756-762 ◽  
Author(s):  
Tate Thigpen ◽  
Andreas duBois ◽  
Jessica McAlpine ◽  
Philip DiSaia ◽  
Keiichi Fujiwara ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Treatment Options ◽  
Gynecologic Cancer ◽  
Tumor Biology ◽  
Specific Treatment ◽  
Dose Schedule ◽  
Consensus Conference ◽  
Cooperative Research ◽  
First Line ◽  
International Consensus

At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients.A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)?A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials?A3: Is the 2004 GCIG-recommended standard comparator arm still valid?A4: What is the role of modifying dose, schedule, and delivery of chemotherapy?A5: What role does surgery play today?

scholarly journals Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

2017 ◽  
Vol 28 ◽  
pp. viii30-viii35 ◽  
Author(s):  
M.A. Bookman ◽  
A. Okamoto ◽  
G. Stuart ◽  
N. Yanaihara ◽  
D. Aoki ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Unmet Needs ◽  
Gynecologic Cancer ◽  
Consensus Conference

Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 763-770 ◽  
Author(s):  
Jonathan A. Ledermann ◽  
Christian Marth ◽  
Mark S. Carey ◽  
Michael Birrer ◽  
David D.L. Bowtell ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Predictive Biomarkers ◽  
Therapeutic Agents ◽  
Careful Consideration ◽  
Consensus Conference ◽  
Molecular Pathways ◽  
New Agents

There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.

The Global Impact of the Gynecologic Cancer InterGroup in Enhancing Clinical Trials in Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 746-749 ◽  
Author(s):  
Monica Bacon ◽  
Henry Kitchener ◽  
Gavin C.E. Stuart ◽  
Jan B. Vermorken
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Oncology ◽  
Gynecologic Cancer ◽  
Consensus Conference ◽  
International Forum ◽  
Gynecologic Cancers ◽  
International Differences ◽  
Global Impact ◽  
Multiple Issues

The Gynecologic Cancer InterGroup (GCIG) has developed from a small network of ovarian cancer researchers to a large international forum addressing multiple issues related to research in gynecologic cancers. Member groups of the GCIG have collaboratively conducted pivotal clinical trials in cancers of the ovary, endometrium, and cervix. The participation of operational and statistical personnel from the GCIG member groups has facilitated a collegial approach to international differences and restrictions.One of the powerful initiatives of the GCIG is the facilitation of the Ovarian Cancer Consensus Conference every few years. The 4th Ovarian Cancer Consensus Conference was held in Vancouver, Canada, in June 2010, and the resulting publications (herein) provide an invaluable resource to researchers in the field of gynecologic oncology.

Ovarian Cancer: The Role of Functional Imaging as an End Point in Clinical Trials

2010 ◽  
Vol 20 (6) ◽  
pp. 971-978 ◽  
Author(s):  
Evis Sala ◽  
Nandita DeSouza ◽  
Susanna I. Lee ◽  
Mostafa Atri ◽  
Hedvig Hricak
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Functional Imaging ◽  
Gynecologic Cancer ◽  
Position Paper ◽  
Gynaecological Cancer ◽  
End Point ◽  
Early Treatment Response ◽  
Anatomical Imaging

The Gynaecological Cancer InterGroup conducts collaborative trials in gynecologic cancer and also aims to develop standards that can be used to strengthen all aspects of study methodology. There is an urgent need to develop more refined imaging end points that can be used as early treatment response biomarkers in ovarian cancer. Therefore, the Gynaecological Cancer InterGroup commissioned an expert position paper on the role of functional imaging as an end point in clinical trials in ovarian cancer. In this position paper, we state the limitation of current anatomical imaging methods used in clinical trials, highlight the potential of functional imaging, and provide key recommendations on the use of functional imaging as an end point in ovarian cancer clinical trials.

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference

2011 ◽  
Vol 21 (4) ◽  
pp. 750-755 ◽  
Author(s):  
Gavin C.E. Stuart ◽  
Henry Kitchener ◽  
Monica Bacon ◽  
Andreas duBois ◽  
Michael Friedlander ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Consensus Statement ◽  
Gynecologic Cancer ◽  
Consensus Conference

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer. This report provides the outcomes from the Fourth Ovarian Cancer Consensus Conference.

ROLE OF ULTRASOUND IN THE DETECTION OF RECURRENT OVARIAN CANCER

2020 ◽  
Vol 6 (1) ◽  
pp. 23-31
Author(s):  
M. Alisherova ◽  
◽  
M. Ismailova
Keyword(s):  
Ovarian Cancer ◽  
Surgical Treatment ◽  
Reproductive System ◽  
Malignant Tumors ◽  
Recurrent Ovarian Cancer ◽  
Primary Diagnosis ◽  
Female Reproductive System

Currently, there are no standard approaches to monitoring patients with ovarian cancer (OC). While the role of ultrasound (US) has been identified in the primary diagnosis of OS, it is still controversial during the subsequent surgical treatment of OC. In world statistics, ovarian cancer is consistently among the four main localizations of malignant tumors of the female reproductive system, along with tumors of the breast, body and cervix.

Counterpoint: Chemosensitivity Assays for Recurrent Ovarian Cancer

2011 ◽  
Vol 9 (1) ◽  
pp. 121-124 ◽  
Author(s):  
Maurie Markman
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Recurrent Ovarian Cancer ◽  
Evidence Based ◽  
Chemosensitivity Assay ◽  
Reliable Evidence ◽  
In Vitro Chemosensitivity ◽  
Frequent Use ◽  
Chemosensitivity Assays

Unfortunately, no reliable evidence-based data have shown any in vitro chemosensitivity assay strategy to be clinically useful in the management of recurrent ovarian cancer, despite frequent use. Several clinical trials have been proposed with the potential to support or refute the relevance of these approaches.

Sign in / Sign up

Export Citation Format

Share Document